Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q3 2021 · 10-Q
Revenue$8.98M$8.98M+0.1% vs Q3 2020 Net Income-$11.58M-$11.58MN/M vs Q3 2020 EPS Diluted-$0.31-$0.31N/M vs Q3 2020 Operating Income-$11,713,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,926,000N/M Margins · derivedOperating margin-130.5%−74.8 pt vs Q3 2020
Net margin-129.0%−74.1 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end